Cargando…

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells

Detalles Bibliográficos
Autores principales:	Stenner, Max-Philipp, Waschbisch, Anne, Buck, Dorothea, Doerck, Sebastian, Einsele, Hermann, Toyka, Klaus V., Wiendl, Heinz
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012825/ http://dx.doi.org/10.1371/annotation/d0ea7ce8-836e-428d-bdfa-5d07bc1b3af2

Ejemplares similares

Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2008)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
por: Trinschek, Bettina, et al.
Publicado: (2013)

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
por: Lee, De-Hyung, et al.
Publicado: (2014)

Correction: FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development
por: Haque, Rizwanul, et al.
Publicado: (2012)

Correction: PSG9 Stimulates Increase in FoxP3(+) Regulatory T-Cells through the TGF-β1 Pathway
Publicado: (2017)

Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis
por: Feuchtenberger, Martin, et al.
Publicado: (2008)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Correction: Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression
Publicado: (2016)

Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3(+) regulatory T cells in humans and mice
por: Bedke, Tanja, et al.
Publicado: (2014)

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Correction: FOXP3+ Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum: The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly
por: Romano, Audrey, et al.
Publicado: (2016)

Correction: Analysis of FOXP3(+) Regulatory T Cells That Display Apparent Viral Antigen Specificity during Chronic Hepatitis C Virus Infection
por: Li, Shuo, et al.
Publicado: (2012)

Correction: CCR7 Expression and Intratumoral FOXP3(+) Regulatory T Cells are Correlated with Overall Survival and Lymph Node Metastasis in Gastric Cancer
Publicado: (2014)

Correction: Foxp3 (−/ATT) Polymorphism Contributes to the Susceptibility of Preeclampsia
por: Chen, Ximing, et al.
Publicado: (2013)

c-Rel is required for the development of thymic Foxp3(+) CD4 regulatory T cells
por: Isomura, Iwao, et al.
Publicado: (2010)

Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis
por: Doerck, Sebastian, et al.
Publicado: (2010)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies
por: Meyer zu Hörste, Gerd, et al.
Publicado: (2014)

Correction: PD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation
por: Kroner, Antje, et al.
Publicado: (2011)

Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study
por: Talmage, Garrick D., et al.
Publicado: (2017)

Correction: Characterization of Protective Human CD4(+)CD25(+) FOXP3(+) Regulatory T Cells Generated with IL-2, TGF-β and Retinoic Acid
por: Lu, Ling, et al.
Publicado: (2011)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

Correction: A Human Trypanosome Suppresses CD8(+) T Cell Priming by Dendritic Cells through the Induction of Immune Regulatory CD4(+) Foxp3(+) T Cells
por: Ersching, Jonatan, et al.
Publicado: (2016)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Correction: SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4(+) T Cells into CD4(+)FoxP3(+) T Regulatory Cells by Production of IFN-γ
por: Madireddi, Shravan, et al.
Publicado: (2012)

Correction: Domain Requirements and Sequence Specificity of DNA Binding for the Forkhead Transcription Factor FOXP3
por: Koh, Kian Peng, et al.
Publicado: (2010)

Correction: Alopecia areata patients show deficiency of FOXP(3)+CD(39)+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease
por: Hamed, Fatma N., et al.
Publicado: (2019)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
por: Korsukewitz, Catharina, et al.
Publicado: (2020)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis
Publicado: (2015)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Correction: Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9)
por: Ehling, Petra, et al.
Publicado: (2013)

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
por: Hemmer, Bernhard, et al.
Publicado: (2023)

Correction: Parallel Evolution of Chordate Cis-Regulatory Code for Development
por: Doglio, Laura, et al.
Publicado: (2013)

Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer
por: Kuwahara, Taichi, et al.
Publicado: (2019)

Correction to: 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes
por: Keller, Sebastian, et al.
Publicado: (2021)

Foxp3(+) Regulatory T Cells in Bone and Hematopoietic Homeostasis
por: Fischer, Luise, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vvgb7kn7s58l29d7l1pgro0pf6